Restricted access advised for MMRV vaccine by CDC advisory panel
The Centers for Disease Control and Prevention (CDC) is currently evaluating a potential update to its immunization schedule, which could see the introduction of the MMRV vaccine for children aged 4 and older.
The MMRV vaccine, manufactured by GlaxoSmithKline (GSK) under the brand name Priorix Tetra, provides protection against measles, mumps, rubella, and varicella (chickenpox). The CDC is emphasizing the importance of maintaining high vaccination rates to protect against outbreaks of these viruses, particularly in light of recent outbreaks in the United States.
The CDC's Advisory Committee on Immunization Practices (ACIP) has voted to modify recommendations for the measles vaccine, with a focus on the use of a single MMRV vaccine for children aged 4 and older. This change is due to a lower risk of febrile seizures in this age group compared to children under 4. However, the ACIP does not recommend MMRV for children under the age of 4 due to a small risk for febrile seizures in that age group.
Febrile seizures, while scary for parents to witness, are generally harmless, according to doctors. They usually last for a few minutes and are caused by fevers associated with viruses or, in some cases, vaccines.
The CDC is committed to ensuring that all individuals have access to necessary vaccines, regardless of their location or socioeconomic status. The organisation is also encouraging healthcare providers to stay up-to-date on the latest recommendations for immunizations and to provide accurate and reliable information to parents about the benefits and risks of vaccination.
As the CDC continues to monitor the safety and effectiveness of the MMRV vaccine, particularly in children under 4, it is actively working to address vaccine hesitancy and to educate the public about the importance of vaccination in maintaining public health. The organisation is working to provide clear and accurate information to healthcare providers and parents about the updated recommendations for the MMRV vaccine.
Read also:
- An Ear Infection Explained: A Discussion on Otitis Media
- Recommendations by CDC advisers for limiting MMRV vaccine choices in younger children, and forthcoming decision on hepatitis B vaccine restrictions.
- October 16th - Volunteer Workforce Training
- High recovery rate for over 90% of patients, asserts the head physician of Almaty's 32nd polyclinic, regarding mobile treatment groups.
